A startup dream has been realized, while an old pharma company tries to turn a new leaf.
On Monday, 60-year-old Purdue Pharma announced a strategic partnership with Exicure, a 2009 startup that could pull as much as $790 million and royalties if its drug candidates succeed.
For that investment, Purdue gets an option and licensing agreement for an investigational psoriasis drug and three other molecules based on the same novel nucleic acid platform.
